The rising costs of healthcare and resource constraints are the top two concerns of pharma and healthcare CEOs, according to PricewaterhouseCoopers 22nd annual global CEO survey.
For its survey, PwC conducted 1,378 interviews in September and October 2018 with CEOs in 91 territories.
Five key findings from the survey:
1. Ninety-three percent of healthcare CEOs said rising costs and ensuing pressures on governments, payers and consumers is the top concern. Eighty-one percent of pharma CEOs agreed.
2. Resource constraints, such as a shortage of talent, was the second biggest concern of healthcare and pharma CEOs.
3. Addressing social determinants of health, such as housing, employment and education was another big concern, with 68 percent of healthcare CEOs and 49 percent of pharma CEOs selecting it as a top concern.
4. In 2019, significantly fewer healthcare and pharma CEOs are optimistic about future organizational growth than in 2018. In particular, only 38 percent of healthcare and 41 percent of pharma CEOs expressed optimism about global growth in 2019, down from 67percent and 51 percent in 2018.
5. The data healthcare and pharma CEOs valued the most were: Brand and reputation (94 percent); financial forecasts and projections (94 percent); customer preferences (93 percent); and any risks facing the business (91 percent).
Read the full report here.